2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management

S Susanibar‐Adaniya, SK Barta - American journal of …, 2021 - Wiley Online Library
Diffuse large B cell lymphoma (DLBCL), the most common type of Non‐Hodgkin lymphoma
(NHL), comprises a heterogeneous group of diseases with different biology, clinical …

Diffuse large B-cell lymphoma

S Li, KH Young, LJ Medeiros - Pathology, 2018 - Elsevier
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma
worldwide, representing approximately 30–40% of all cases in different geographic regions …

PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia

Z Gu, ML Churchman, KG Roberts, I Moore, X Zhou… - Nature …, 2019 - nature.com
Recent genomic studies have identified chromosomal rearrangements defining new
subtypes of B-progenitor acute lymphoblastic leukemia (B-ALL), however many cases lack a …

Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures

N Kotlov, A Bagaev, MV Revuelta, JM Phillip… - Cancer discovery, 2021 - AACR
Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous
disease. Transcriptomic and genetic characterization of DLBCL has increased the …

Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma

D Ennishi, A Jiang, M Boyle, B Collinge… - Journal of Clinical …, 2019 - ascopubs.org
Purpose High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
(HGBL-DH/TH) has a poor outcome after standard chemoimmunotherapy. We sought to …

Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker …

A Rosenwald, S Bens, R Advani, S Barrans… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE MYC rearrangement (MYC-R) occurs in approximately 10% of diffuse large B-
cell lymphomas (DLBCLs) and has been associated with poor prognosis in many studies …

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

NA Johnson, GW Slack, KJ Savage… - Journal of clinical …, 2012 - ascopubs.org
Purpose Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with
rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). MYC …

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

AM Petrich, M Gandhi, B Jovanovic… - Blood, The Journal …, 2014 - ashpublications.org
Patients with double-hit lymphoma (DHL), which is characterized by rearrangements of MYC
and either BCL2 or BCL6, face poor prognoses. We conducted a retrospective multicenter …

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene …

S Hu, ZY Xu-Monette, A Tzankov… - Blood, The Journal …, 2013 - ashpublications.org
Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal
center B-cell (GCB)–like and unfavorable activated B-cell (ABC)–like subtypes based on …

Diagnosis and classification of hematologic malignancies on the basis of genetics

J Taylor, W Xiao, O Abdel-Wahab - Blood, The Journal of the …, 2017 - ashpublications.org
Genomic analysis has greatly influenced the diagnosis and clinical management of patients
affected by diverse forms of hematologic malignancies. Here, we review how genetic …